Klinefelter综合征代谢与2型糖尿病的全生命周期研究
基于丹麦全国登记数据,比较未诊断、诊断未治疗及睾酮替代治疗的Klinefelter综合征(KS)男性与对照的代谢障碍发生率。KS总体代谢病风险增加超过2倍,2型糖尿病HR 2.56(1.85-3.44);未诊断KS代谢表型最重,诊断后2型糖尿病全因死亡率在未治疗组升高(HR 1.77 [1.28-2.45]),治疗组与对照无差异。
要点
- KS男性2型糖尿病风险增加超过2倍,HR 2.56(1.85-3.44)。
- 未诊断KS代谢表型最重,肥胖和晚期糖尿病并发症更多。
- 诊断未治疗KS在2型糖尿病后全因死亡率升高,治疗组与对照无差异。
核心结论
- KS男性代谢表型取决于诊断和治疗状态,未诊断者代谢功能障碍最显著。
- 需提高KS诊断和治疗以减轻代谢障碍并改善生存。
主要发现
- KS代谢病发生率增加超过2倍,2型糖尿病HR 2.56(1.85-3.44)。
- 未诊断KS较治疗KS肥胖更多,晚期糖尿病并发症HR 2.83(1.33-6.02)。
- 诊断未治疗KS在2型糖尿病后全因死亡率较对照升高HR 1.77(1.28-2.45),治疗KS与对照无差异HR 1.30(0.68-2.48)。
临床怎么用
- 对KS男性应早期诊断并评估代谢风险,尤其2型糖尿病筛查。
- 未治疗KS需关注糖尿病并发症和死亡风险,及时启动睾酮治疗可能改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Klinefelter syndrome (KS) is underdiagnosed, undertreated, and associated with metabolic dysfunction. OBJECTIVE: We compared incidences of metabolic disorders among men with KS, either undiagnosed (U-KS), diagnosed and untreated (D-KS), or treated with testosterone replacement therapy (T-KS). METHODS: This was a national Danish registry-based study from January 1994 to December 2022. We computed hazard ratios (HR) for incidence and severity of metabolic disorders between risk set matched strata of U-KS, D-KS, and T-KS and male control individuals. We evaluated the effect of parenteral vs transdermal testosterone supplementation on incidence of metabolic disorders in T-KS, applying inverse probability weighting. RESULTS: We included 508 age-matched strata of U-KS, D-KS, and T-KS, and included 46 241 male controls. Incidence of metabolic conditions was more than 2-fold increased in KS, including type 2 diabetes (HR 2.56 [1.85-3.44]). U-KS presented with the most severe metabolic phenotype, with more obesity and more late-stage diabetes complications compared with T-KS (HR 2.83 [1.33-6.02]). All-cause mortality following diagnosis of type 2 diabetes was increased in D-KS compared with controls (HR 1.77 [1.28-2.45]), but nondifferential for T-KS and controls (HR 1.30 [0.68-2.48]). We saw a pattern of less obesity and type 2 diabetes, but more hypertension and hypercholesterolemia, with parenteral vs transdermal testosterone supplementation in T-KS. CONCLUSION: The metabolic profile in men with KS is dependent on diagnosis and treatment status, with pronounced metabolic dysfunction in U-KS. Better diagnosis and treatment of KS are needed to alleviate metabolic dysfunction and improve survival in men with KS.
引用
- Chang S, Pedersen L, Skakkebæk A, et al. Metabolism and Type 2 Diabetes Across Life Stages in Klinefelter Syndrome: A Population-Based Cohort Study. J Clin Endocrinol Metab. 2026. PMID: 41237827. doi:10.1210/clinem/dgaf619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。